Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare.
Nicola Squillace(Azienda Ospedaliera San Gerardo), Paolo Bonfanti(University of California San Diego), Guglielmo Marco Migliorino(Azienda Ospedaliera San Gerardo), Paolo Maggi(Università degli Studi di Enna Kore), Laura Cordier(Luigi Sacco Hospital), Benedetto Maurizio Celesia(Ospedale Garibaldi), Giuseppe Vittorio De Socio(University of Perugia), M. Mameli(University of Sassari), Elena Ricci(Mario Negri Institute for Pharmacological Research), Canio Martinelli(Azienda Ospedaliero-Universitaria Careggi), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), E Salomoni(University of Sassari), Simone Passerini(Office of Infectious Diseases), Antonio Di Biagio, Giovanni Francesco Pellicanò(University of Messina), Katia Falasca(University of Chieti-Pescara)
Cited by 0
Related Papers
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208